New drug cocktail shows promise against Hard-to-Treat lung cancer brain spread
NCT ID NCT06812871
First seen Apr 18, 2026 · Last updated May 24, 2026 · Updated 7 times
Summary
This study tested a combination of three drugs—high-dose furmonertinib, bevacizumab, and pemetrexed given into the spinal fluid—in 46 people with a specific type of lung cancer (EGFR-mutated) that had spread to the lining of the brain. The goal was to see if this treatment could control the cancer in the brain and body. While the approach aims to manage the disease, patients may still need ongoing therapy, so this is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.